mRNA-2151 / Moderna - LARVOL DELTA

Moderna Science Day Highlights Expanding Potential of mRNA Platform (Investing News Network (INN)) - "Early Pipeline Progress: The Phase 1 study is ongoing with mRNA-4106 as monotherapy in advanced solid tumors...mRNA-4359 (Cancer antigen therapy): Designed to elicit T-cell immune responses against tumor and immunosuppressive cells, the Phase 1/2 study is ongoing with the Phase 2 portion including cohorts in first-line metastatic melanoma and first-line metastatic non-small cell lung cancer (NSCLC)....mRNA-2808 (T-cell engager): Designed to use multiplexed T-cell engagers to improve efficacy and overcome mechanisms of resistance for multiple myeloma, the Phase 1/2 study is ongoing and includes three distinct T-cell engagers against clinically validated targets....mRNA-2151 (T-cell engager)....this preclinical multiplexed T-cell engager program is moving toward early development in ovarian cancer."

Preclinical • Trial status • Melanoma • Multiple Myeloma • Non Small Cell Lung Cancer • Ovarian Cancer • Solid Tumor